Sanofi signs $805 million deal for MS drug

05:20 EST 10 Nov 2017 | Pharmafile

Sanofi has decided to build its pipeline in neurological disorders with the agreement to develop Principia Biopharma’s BTK inhibitor candidate for multiple sclerosis (MS). The deal works out at $40 million upfront and there is a further $765 million lying in-wait for Principia, dependent upon milestone payments.

read more

Original Article: Sanofi signs $805 million deal for MS drug


More From BioPortfolio on "Sanofi signs $805 million deal for MS drug"

Quick Search


Relevant Topics

Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...